Ionizable lipid nanoparticles for RAS protease delivery to inhibit cancer cell proliferation.

ABSTRACT: Mutations in RAS, a family of proteins found in all human cells, drive a third of cancers, including many pancreatic, colorectal, and lung cancers. However, there is a lack of clinical therapies that can effectively prevent RAS from causing tumor growth. Recently, a protease was engineered that specifically degrades active RAS, offering a promising new tool for treating these cancers. However, like many other intracellularly acting protein-based therapies, this protease requires a delivery vector to reach its site of action within the cell. In this study, we explored the incorporation of cationic lipids into ionizable lipid nanoparticles (LNPs) to develop a RAS protease delivery platform capable of inhibiting cancer cell proliferation in vitro and in vivo. A library of 13 LNPs encapsulatin

SUBMITTER: Atsavapranee E 

PROVIDER: S-EPMC11210981 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature